The therapeutic benefits of CBD never cease to amaze us. The Israeli-Canadian company Innocan Pharma has recently advanced medical research regarding the use of cannabidiol (CBD) as a pharmaceutical treatment.
CBD is the second most active molecule in the cannabis plant. Unlike THC, it does not produce any psychotropic effects. It is now considered a reliable treatment for various pathologies such as chronic pain, stress, anxiety, or epilepsy.
Every day, more and more patients are reporting major pain relief thanks to the therapeutic benefits of CBD.
For several years now, researchers were faced with a significant obstacle in regards to the CBD molecule. Why? CBD has low oral bioavailability and breaks down very quickly in the human body. This means that the therapeutic effects of CBD are drastically reduced in the treatment of diseases such as multiple sclerosis, rheumatoid arthritis, or even epilepsy.
Following a clinical trial conducted on animals, researchers at Innocan Pharma, discovered that the administration of CBD encapsulated in liposomes demonstrated initial positive results by creating effective and long-lasting therapeutic effects while maintaining significant levels of CBD in the body for an extended time.
“During our experiments with dogs, we noticed promising results in the treatment of various diseases,” said Iris Bincovich, CEO of Innocan Pharma.
“A long-term treatment of one month, possible thanks to the LPT platform, would be a major innovation for animals as well as for humans,” added the CEO.
The pharmaceutical company is currently working on launching human clinical trials. The company also wants to focus its research on making liposomes loaded with CBD in larger quantities to create capsules for medical use.